Jellatech Secures $5.5M in Seed Funding to Revolutionize Biomedical Applications with Human Proteins

Jellatech, the innovative B2B biotech company based in Raleigh, NC, is excited to announce that it has successfully raised $5.5 million in funding to further advance its mission of transforming biomedical applications through human-identical proteins. Specializing in the production of human proteins using unique cell-based technology, Jellatech is positioned to impact health and longevity significantly, beginning with the production of Type I collagen. As the only company offering a reliable and consistent supply of bio-identical human collagen, Jellatech is poised to disrupt the existing market, which traditionally relies on tissue-extracted bovine and porcine sources. With the global biomedical collagen market expected to exceed $2.4 Billion by 2032, Jellatech envisions a much larger Total Addressable Market (TAM) for human collagen—potentially reaching between $100 to $150 billion. The new funding will be strategically directed towards expanding Jellatech's capabilities in tissue regeneration, injectable aesthetics, cell and gene therapy, and other therapeutic applications. This capital infusion allows Jellatech to accelerate research and development, enhance production scalability, and ultimately drive breakthroughs that can revolutionize healthcare. The team is motivated to collaborate with partners throughout the industry as they unlock new possibilities and spearhead advancements that focus on improving human health. Jellatech believes that this is just the beginning, and the vast potential for innovation in the biotech space is limitless. Stakeholders interested in exploring partnerships are encouraged to reach out, as Jellatech is committed to redefining the future of biomedical applications and creating a brighter tomorrow.